


Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-149B7170-F416-43D1-8830-D8ABECD1639D_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M56830_02_01
 DOI Ref: qv749

© 2025 USPC
 Do not distribute

Nitrofurazone



$C_6H_6N_4O_4$ 198.14

Hydrazinecarboxamide, 2-[(5-nitro-2-furanyl)methylene]-;

5-Nitro-2-furaldehyde semicarbazone CAS RN®: 59-87-0; UNII: X8XI70B5Z6.

DEFINITION

Nitrofurazone contains NLT 98.0% and NMT 102.0% of nitrofurazone ($C_6H_6N_4O_4$), calculated on the dried basis.

[NOTE—Avoid at all times exposing solutions of nitrofurazone to direct sunlight, excessive heat, strong fluorescent lighting, and alkaline materials.]

IDENTIFICATION

Change to read:

- A. [▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#) ▲ (CN 1-MAY-2020)

Change to read:

- B. [▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Ultraviolet-Visible Spectroscopy: 197U](#) ▲ (CN 1-MAY-2020)

Sample solution: 8 µg/mL, prepared as directed in the Assay

Acceptance criteria: The ratio A_{306}/A_{375} is NMT 0.25.

ASSAY

• PROCEDURE

Standard stock solution: 0.4 mg/mL of [USP Nitrofurazone RS](#) prepared as follows. Transfer 100 mg of [USP Nitrofurazone RS](#) to a 250-mL volumetric flask. Dissolve in 50 mL of dimethylformamide, and dilute with water to volume.

Standard solution: 8 µg/mL of [USP Nitrofurazone RS](#) in water from *Standard stock solution*

Sample stock solution: 0.4 mg/mL of Nitrofurazone prepared as follows. Transfer 100 mg of Nitrofurazone to a 250-mL volumetric flask. Dissolve in 50 mL of dimethylformamide, and dilute with water to volume.

Sample solution: 8 µg/mL of Nitrofurazone in water from *Sample stock solution*

Instrumental conditions

Mode: UV-Vis

Analytical wavelength: 375 nm

Cell: 1 cm

Blank: Water

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of nitrofurazone ($C_6H_6N_4O_4$) in the portion of Nitrofurazone taken:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times 100$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of [USP Nitrofurazone RS](#) in the *Standard solution* (µg/mL)

C_U = concentration of Nitrofurazone in the *Sample solution* (µg/mL)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

• **RESIDUE ON IGNITION (281):** NMT 0.1%

• ORGANIC IMPURITIES

Mobile phase: Acetonitrile and water (40:60)

Peak identification solution: 0.1 mg/mL each of [USP Nitrofurazone Related Compound A RS](#) and [USP Nitrofurfural Diacetate RS](#) in *Mobile phase*

System suitability solution: 0.1 mg/mL each of [USP Nitrofurazone RS](#) and [USP Nitrofurantoin RS](#) in *Mobile phase*

Standard solution: 5 µg/mL of [USP Nitrofurazone RS](#) in *Mobile phase*

Sample solution: 1 mg/mL of Nitrofurazone in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 310 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Flow rate: 1 mL/min

Injection volume: 20 µL

Run time: NLT 10 times the retention time of nitrofurazone

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for nitrofurazone and nitrofurantoin are about 1.0 and 1.1, respectively.]

Suitability requirements

Resolution: NLT 2.0 between nitrofurazone and nitrofurantoin, *System suitability solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Peak identification solution*, *Standard solution*, and *Sample solution*

Calculate the percentage of each impurity in the portion of Nitrofurazone taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_S = peak response of nitrofurazone from the *Standard solution*

C_S = concentration of [USP Nitrofurazone RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Nitrofurazone in the *Sample solution* (mg/mL)

F = relative response factor (see [Table 1](#))

Acceptance criteria: See [Table 1](#). Disregard any peak less than 0.05%.

Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Nitrofurazone	1.0	—	—
Nitrofurfural diacetate	3.4	2.2	0.5
Nitrofurazone related compound A	6.0	1.6	0.5

